Biotech Archives - Page 98 of 795

4 minute read

Atara Biotherapeutics Announces Submission Of Investigational New Drug Application For ATA3219 For Treatment Of Lupus Nephritis

February 14, 10:03 AM

ATA3219 is an Allogeneic CAR T-Cell Therapy Targeting CD19+ B Cells to Potentially Address the Root Cause of Lupus Nephritis (LN)ATA3219 Is Designed to Combine the Natural Biology of Unedited T Cells and the Benefits of

ATRA

3 minute read

IN8bio Announces Publication On Novel Gamma-Delta T Cell Therapy For Glioblastoma In Frontiers In Immunology

By Benzinga Newsdesk

February 14, 9:17 AM

IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a publication in Frontiers in Immunology that reviews IN8bio's novel

INAB

3 minute read

MiNK Therapeutics, Inc. Announces First Refractory Gastric Cancer Patient Dosed In Phase 2 Trial With Novel Combination Of Co’s Allogeneic INKT Cell Therapy And Agenus’ Botensilimab And Balstilimab

By Benzinga Newsdesk

February 14, 9:13 AM

Dr. Yelena Janjigian, Chief of GI Cancers, Leads Investigator Sponsored Study at Memorial Sloan Kettering Cancer Center Trial is Supported by Stand Up To Cancer as Part of an Initiative to Find Treatments for the

INKT

4 minute read

Tonix Pharmaceuticals Hosted KOL Webinar On Phase 3 Fibromyalgia Trial For Tonmya, Plans To File NDA For FDA Approval In Second Half Of 2024

By Benzinga Newsdesk

February 14, 9:12 AM

Clinical results show that Tonyma™ has broad-spectrum activity, addressing the three core fibromyalgia symptoms: pain, fatigue, and sleep disturbance Tonmya™ has a favorable tolerability profile

TNXP

3 minute read

Erasca Announces Two Clinical Trial Collaboration And Supply Agreements For Trametinib To Evaluate Naporafenib Combination In SEACRAFT-1 And SEACRAFT-2 Trials

By Benzinga Newsdesk

February 14, 9:10 AM

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initial SEACRAFT-1 Phase 1b combination data in RAS Q61X solid tumors expected between Q2-Q4

ERAS

3 minute read

Carrick Therapeutics Announces First Patient Dosed In Phase 1b/2 Clinical Trial Of Samuraciclib In Combination With Vepdegestrant In Patients With Advanced Breast Cancer

By Benzinga Newsdesk

February 14, 9:05 AM

Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the first patient has been dosed in its Phase 1b/2 clinical trial

ARVN

2 minute read

Pulse Biosciences Announces 60-Day Follow-Up Evaluations For Initial Patients Treated In The CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study

By Benzinga Newsdesk

February 14, 9:02 AM

Pulse Biosciences, Inc. (NASDAQ:PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today

PLSE

6 minute read

Ipsen’s Onivyde Regimen, A Potential New Standard-Of-Care First-Line Therapy In Metastatic Pancreatic Adenocarcinoma, Approved By FDA

By Benzinga Newsdesk

February 13, 5:50 PM

Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde® regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically meaningful improvements in overall survival and

IPSEY

3 minute read

Sana Biotechnology Announces Publication Of Preclinical Diabetes Data In Cell Stem Cell Demonstrating Insulin Independence Following Transplantation Of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression In A Diabetic NHP

By Benzinga Newsdesk

February 13, 5:43 PM

Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence without immunosuppression

SANA

1 minute read

CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst

By Vandana Singh

February 13, 3:05 PM

Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800 million.

CBAY